PCMA Recommends Streamlining Health Plan Requirements to Better Serve Medicare Beneficiaries
PCMA recently provided several recommendations to the Department of Health & Human Services (HHS) that would streamline and simplify requirements for Medicare Advantage and Part
PCMA Urges CMS to Protect Pharmacies in Medicare Fair Price Program
Under the Inflation Reduction Act (IRA), for designated drugs that are negotiated by CMS in Medicare Part D, the pharmacy is no longer paid by
PCMA Provides Recommendations for 2026 Medicare Plan Year to Promote Lower Costs and Better Pharmacy Experiences for Patients
By Debjani Mukherjee, Senior Director, Regulatory Affairs, PCMA In November, the Centers for Medicare & Medicaid Services (CMS) released a proposed rule for the Medicare
Drug Formularies: Purposes, Intent, and Challenges
A plan’s formulary (or drug list) is a list of prescription drugs approved for coverage by plan sponsors such as public and private employers, unions,
PCMA Urges CMS to Stabilize the Medicare Part D Plan Marketplace
By Tim Dube, SVP, Policy and Regulatory Insights, Pharmaceutical Care Management Association Last week, PCMA offered recommendations to the Centers for Medicare and Medicaid Services
CMS Should Protect the Financial Health of Pharmacies When Implementing the IRA
By Tim Dube, SVP, Policy and Regulatory Insights, Pharmaceutical Care Management Association If the community pharmacy lobby is right, America’s Medicare beneficiaries may not be
